1.
Xu L, Shadman M, Flinn IW, Levy MY, Porter R, Burke JM, Zafar SF, Cultrera JL, Misleh J, Kingsley EC, Yimer HA, Freeman B, Chaudhry A, Tumula PK, Gandhi MD, Crescenzo R, By K, Cohen A, Chen D-Y, Idoine A, Manda S, Sharman JP, Ramakrishnan V. Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies. haematol [Internet]. 2020Sep.10 [cited 2024Apr.20];. Available from: https://haematologica.org/article/view/haematol.2023.283861